Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Full text

Abstract

Free full text

Publication Types

Randomized Controlled Trial

Journal Article

Research Support, Non-U.S. Gov't

Clinical Trial, Phase III

Comparative Study

Letter

Research Support, N.I.H., Extramural

Publication Year

From

Quick links

Individual year

2021

2019

2018

2014

2013

2011

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for

""Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination""[mesh_terms]

6 Results

Searching titles within these results

Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).

Lisa Hamzah, Juan M Tiraboschi, Helen Iveson, Martina Toby, Christine Mant, John Cason, Keith Burling, Emily Wandolo, Isabelle Jendrulek, Chris Taylor, Fowzia Ibrahim, Ranjababu Kulasegaram, Alastair Teague, Frank A Post, Julie Fox

Antiviral therapy 2018;21(4):287-96

Full Text

Abstract

A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.

Jhon Rojas, Jose L Blanco, Sonsoles Sanchez-Palomino, Maria A Marcos, Alberto C Guardo, Ana Gonzalez-Cordon, Montserrat Lonca, Amparo Tricas, Ana Rodriguez, Anabel Romero, Jose M Miro, Josep Mallolas, Jose M Gatell, Montserrat Plana, Esteban Martinez

AIDS (London, England) 2019;32(12):1633-1641

Full Text

Abstract

A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet.

Jennifer King, Matthew McCall, Anthony Cannella, Michael Anne Markiewicz, Amanda James, Chantelle B Hood, Edward P Acosta

Journal of acquired immune deficiency syndromes (1999) 2011;56(5):e130-2

Full Text

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Edwin DeJesus, Jürgen K Rockstroh, Monica L Walker, Randi Leavitt, Anthony J Rodgers, Jeffrey L Lennox, Hong Wan, Mark J DiNubile, Yazdan Yazdanpanah, Michael S Saag, Bach-Yen Nguyen, Peter Sklar, Hedy Teppler, Michael Miller

Journal of acquired immune deficiency syndromes (1999) 2013;63(1):77-85

Full Text

Abstract

Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.

Samir K Gupta, Deming Mi, Sharon M Moe, Michael P Dubé, Ziyue Liu

Journal of acquired immune deficiency syndromes (1999) 2014;64(3):279-83

Free Full Text

Abstract

Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.

Patawee Boontanondha, Hataikarn Nimitphong, Suchawadee Musikarat, Aschara Ragkho, Sasisopin Kiertiburanakul

Current HIV research 2021;18(1):52-62

Free Full Text

Abstract

Results: 1 – 6 / 6

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination""[mesh_terms]

Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).

A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.

A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet.

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.

Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.

Results for

""Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination""[mesh_terms]